|Title:||Combination of atovaquone with proguanil for the treatment of protozoal infections|
|Abstract:||The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.|
|Inventor(s):||Gutteridge; Winston Edward (Beckenham, GB), Hutchinson; David Brian Ashton (Beckenham, GB), Latter; Victoria Susan (Beckenham, GB), Pudney; Mary (Beckenham, GB)|
|Assignee:||Glaxo Wellcome Inc. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Formulation;|
Field: Not categorized
Back Citations: 22nd percentile
Forward Citations: 1st percentile
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9224739||Nov 26, 1992|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||517||► subscribe|
|African Regional IP Organization (ARIPO)||9300592||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.